DOCSLIB.ORG

What Is Histamine? - Looks Simple

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What Is Histamine? - Looks Simple 5/31/2017 What is histamine? - Looks simple. Made from aminoacid histidine. histamine histidine H H N N N N N H N H H H O OH pK 's = 5.7, 9.8 a pKa's = 1.9, 6.0, 9.3 How is it made – Handout. What does it do? – Four different receptors known now. All part of G protein- coupled family. H1 – immune response that causes hives, makes blood vessels leaky H2 – stimulates stomach acid secretion, H3 – found in CNS and can inhibit release of other neurotransmitters, H4 - found in bone marrow and white blood cells and regulates neutrophil release from bone marrow. It is also expressed in the colon, liver, lung, small intestine, spleen, testes, thymus, tonsils, and trachea 1 © Oxford University Press, 2013 Hives also known as urticaria, is a kind of skin rash with red, raised, itchy bumps. They may also burn or sting. Often the patches of rash move around. Hives often occur following an infection or as a result of an allergic reaction such as to medication, insect bites, food, psychological stress, cold temperature, or vibrations. In half of cases the cause remains unknown. Risk factors include having conditions such as hay fever or asthma. Diagnosis is typically based on the appearance. Patch testing may be useful to determine the allergy. Prevention is by avoiding whatever it is that causes the condition. Typically they last a few days and do not leave any long -lasting skin changes . Fewer than 5% of cases last for more than six weeks. The condition frequently recurs. Treatment is typically with antihistamines such as diphenhydramine and ranitidine. In severe cases, corticosteroids or leukotriene inhibitors may also be used. Antihistamines that block the histamine H1 receptors are the first line of therapy. About 20% of pppeople are affected. Cases of short duration occur equally in males and females while cases of long duration are more common in females. Cases of short duration are more common among children while cases of long duration are more common among those who are middle aged. Hives have been described at least since the time of Hippocrates. The term urticaria is from the Latin urtica meaning "nettle“. 2 © Oxford University Press, 2013 1 5/31/2017 Peptic ulcer disease (PUD), is a break in the lining of the stomach, first part of the small intestine, or occasionally the lower esophagus. An ulcer in the stomach is known as a gastric ulcer while that in the first part of the intestines is known as a duodenal ulcer. Common symptoms upper abdominal pain that improves with eating. Other symptoms include belching, vomiting, weight loss, or poor appetite. About a third of older people have no symptoms. Complications may include bleeding, (15% of people) with an ulcer perforation, and blockage of the stomach. Common causes include the bacteria Helicobacter pylori and non-steroidal anti-inflammatory drugs (NSAIDs). Other less common causes include tobacco smoking, stress due to serious illness, Crohn disease and liver cirrhosis, among others. H. pylori can be diagnosed by testing the blood for antibodies or a biopsy of the stomach. Diet does not play an important role in either causing or preventing ulcers . Treatment includes stopping smoking , stopping NSAIDs, stopping alcohol, and medications to decrease stomach acid. The medication used to decrease acid is usually either a proton pump inhibitor (PPI) or an H2 blocker . Ulcers due to H. pylori are treated with a combination of medications such as amoxicillin, clarithromycin, and a PPI. Peptic ulcers are present in around 4% of the population. They newly began in around 87.4 million persons worldwide in 2015. About 10% of people develop a peptic ulcer at some point in their life. They resulted in 267,500 deaths in 2015 down from 327,000 deaths in 1990. 3 © Oxford University Press, 2013 In the early 1960s only one class of antihistamine was known (H1 now) First generation antihistamines Clinically, H1-antihistamines are used to treat allergic reactions and mast cell-related disorders. Sedation is a common side effect of H1-antihistamines that readily cross thbldhe blood–bibbrain barr ier; some o fhf these drugs, suc h as N O diphenhydramine and doxylamine, are therefore used to treat insomnia. H1-antihistamines can also reduce inflammation. diphenhydramine (Benadryl) 4 © Oxford University Press, 2013 2 5/31/2017 Second generation antihistamines Mepyramine crosses the blood–brain barrier to a much lower degree than the first-generation N antihistamines. Their main benefit is they N primarily affect peripheral histamine receptors (as opposed to the CNS) and therefore are less O N sedating. However, high doses can still induce the central nervous system drowsiness. The reason Mepyramine for their peripheral selectivity is that most of these compounds are zwitterionic at physiological pH (around pH 7.4). As such, they are very polar, meaning that they do not easily cross the blood– brain barrier and act mainly outside the central nervous system. Possible synthesis O O NH2 H N N N H C H O H N N O Cl N O N O Mepyramine 5 © Oxford University Press, 2013 Second generation antihistamines Ketotifen is a noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold ketotifen O as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, S it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks. Ketotifen relieves and prevents eye itchiness and/or irritation associated with most seasonal allergies. It starts working within minutes after N administering the drops. The mean elimination half life is 12 hours. It was known that histamine stimulated stomach acid, but none of the known antihistamines inhibited acid secretion. 6 © Oxford University Press, 2013 3 5/31/2017 ANTI-ULCER AGENTS - HISTAMINE ANTAGONISTS Ulcers •Localised erosions of the mucous membranes of the stomach and duodenum •Potentially fatal if untreated •Caused by stress, infection (H. Pylori), smoking and drugs (NSAIDS) •Agrevated by gastric acid (HCl) in the stomach •Estimated 1 out of 10 people will have one sometime in their life Therapy of ulcers •Old days: antacids, bland diet (crackers, milk), surgery on stomach •New days: •Lower the levels of gastric acid a. histam ine antagon ists and b. proton pump inhibitors •Antibacterial agents vs. H. Pylori •Herbal remedies 7 © Oxford University Press, 2013 Parietal cells and gastric acid release Acetylcholine oesophagus Histamine Gastrin + M + 3 + H2 Cck2 cAMP + + + Parietal Cells - Stomach H+ Cl Stomach HCl Antrum Pyloric Receptors Sphincter Ion channel Duodenum Proton pump Notes •Release of gastric acid is promoted by acetylcholine, gastrin and histamine 8 © Oxford University Press, 2013 4 5/31/2017 sulfonated tyrosine O3SO O CO2 CO2 H Glu Glu Ala Met Phe N Pro Leu Gly Gly Trp Glu Glu Glu N Trp Asp NH3 O H CO O C CO O CO modified Glu 2 2 2 2 gastrin - peptide hormone (made by G cells) O CH3 H3N H2 CH3 C N N H H3C O C CH H 3 2 N acetyl choline histamine 9 © Oxford University Press, 2013 10 © Oxford University Press, 2013 5 5/31/2017 Biosynthesis of histamine from the amino acid histidine (with vitamine B6) H B H B H H O HO O CO2H N O N N H H NH OH H N -2 N O3PO H B H B N histidine (pKa's = 1.8, 6.1, 9.3) H N PLP - vitamine B6 (aldehyde version) H B B H B H H O O O H C O O N C N N H H NH H NH N NH N N A similar process occurs with H B many other amino acids, including synthesis of neurotransmitters serotonin and N dopamine (which forms N PLP - vitamine B6 N epinephrine and norepinephrine). (imine version) H Glutamate can react in a similar H H manner. B H O H H B Histamine is released when O N cells are damaged. It N increases the permeabililty H NH N of small blood vessels and NH allows white blood cells HN H into that area to defend H against infection. Allergic N reactions and irritation are histamine common side effects. H N PLP - vitamine B6 (aldehyde version) 11 H © Oxford University Press, 2013 Histamine - Properties Notes •A chemical messenger released by cells •Two possible tautomers •Acts as a local hormone •pKa for the -NH2 group = 9.80. •% ionisation at pH 7.4 = 99.6 •pKa for the imidazole ring = 5.74 •Imidazole ring is slightly ionized at blood pH Percent conjugate acid and conjugate base plasma pH = 7.4 H N N H N H pKa1 = 5.7 pKa2 = 9.8 N N N HN H HN H HN H H H H [B:] [B:] pH - pKa = log pH - pKa = log What could make the [HB+] [HB+] pKa go higher or lower? [B:] [B:] 7.4 - 5.7 = 1.7 = log 7.4 - 9.8 = -2.4 = log The conjugate acid is [HB+] [HB+] positive and the [B:] [B:] =101.7 =50/1=98%/2% =10-2.4 = 1 / 250 = 0.4% / 99.6% conjugate base is neutral. [HB+] [HB+] Two tautomer possibilities BH H H H N N N N N N N N H H H3N H3N H H3N H3N is closer to the side chain B H N How does the pKa of imidazole compare to pKa1 of histamine? N H (higher, lower or similar)? 12 © Oxford University Press, 2013 6 5/31/2017 Histamine Actions Histamine is released by cell damage Stimulates dilation of blood vessels with increased permeability White blood cells escape blood vessels and access area of tissue damage White blood cells combat infection BUT Histamine is also released by allergies, asthma, hay fever and insect bites 13 © Oxford University Press, 2013 Classical antihistamines Commonly used to treat symptoms such as inflammation & itching MeO NMe2 NMe2 O N N Mepyramine Diphenhydramine Benadryl •But no effect on gastric acid release •Casts doubt on histamine receptors being present on parietal cells •Histamine may promote gastric
Load more

Recommended publications
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active
    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
    [Show full text]
  • Diphenhydramine Hydrochloride (CASRN 147-24-0) in F344/N Rats
    NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 355 TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIPHENHYDRAMINE HYDROCHLORIDE (CAS NO. 147-24-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) LJ.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health NTP ‘TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIPHENHYDRAMINE HYDROCHLORIDE (CAS NO. 147-24-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) R. Melnick, Ph.D., Study Scientist NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 September 1989 NTP TR 355 NIH Publication No. 89-2810 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health CONTENTS PAGE ABSTRACT ................................................................ 3 EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY .................. 6 CONTRIBUTORS ............................................................ 7 PEERREVIEWPANEL ........................................................ 8 SUMMARY OF PEER REVIEW COMMENTS ......................................... 9 I. INTRODUCTION ........................................................ 11 I1. MATERIALS AND METHODS .............................................. 21 III. RESULTS ............................................................. 35 RATS ............................................................. 36 MICE ............................................................. 45 GENETIC TOXICOLOGY ............................................... 53 IV.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Role of Dietary Histidine in the Prevention of Obesity and Metabolic Syndrome
    Open access Editorial Open Heart: first published as 10.1136/openhrt-2017-000676 on 1 July 2018. Downloaded from Role of dietary histidine in the prevention of obesity and metabolic syndrome James J DiNicolantonio,1 Mark F McCarty,2 James H OKeefe 1 To cite: DiNicolantonio JJ, HISTIDINE SUPPLEMENTATION AMELIORATES histidine dose dependently increases hypo- McCarty MF, OKeefe JH. Role of METABOLIC SYNDROME thalamic levels of histamine as well as hypo- dietary histidine in the prevention of obesity and A recent Chinese supplementation study, in thalamic activity of histidine decarboxylase, metabolic syndrome. Open Heart which obese middle-aged women diagnosed the enzyme which converts histidine to hista- 10 2018;5:e000676. doi:10.1136/ with metabolic syndrome received 12 weeks mine. Such administration also inhibits food openhrt-2017-000676 of supplemental histidine (2 g, twice daily) or consumption—an effect that is blocked in matching placebo, achieved remarkable find- animals pretreated with an irreversible inhib- 1 Accepted 24 April 2018 ings. Insulin sensitivity improved significantly itor of histidine decarboxylase. in the histidine-supplemented subjects, and Neuronal histamine release in the hypo- this may have been partially attributable to thalamus is subject to feedback regulation loss of body fat. Body mass index (BMI), waist by presynaptic H3 receptors. In rodent circumference and body fat declined in the studies, antagonists and inverse agonists for histidine-supplemented group relative to the these receptors have been shown to mark- placebo group; the average fat loss in the histi- edly amplify hypothalamic histamine levels, dine group was a robust 2.71 kg. Markers of suppress feeding, decrease body weight and systemic inflammation such as serum tumour enhance metabolic rate.11–15 Such agents may necrosis factor-alpha (TNF-α) and inter- have clinical potential for managing obesity.
    [Show full text]
  • Pharmacology and Toxicology of Metiamide, a Histamine H
    9 November 1974 S.-A. MEDIESE TYDSKRIF 2253 Pharmacology and Toxicology of Metiamide, a - Histamine H2 Receptor Antagonist R. W. BRIMBLECOMBE, W. A. M. DUNCAN, M. E. PARSONS SUMMARY x 10-'M on atrial muscle and 7,5 x lO-rM on uterine muscle. Even. at lO-'M, metiamide did not inhibit the A brief review of the pharmacology and toxicology of effects of isoprenaline on either of these tissues neither did it inhibit the effects of histamine on isolated Quinea- metiamide, a histamine H2-receptor antagonist, is given, ~ and evidence is presented to support the view that it pig ileum (mediated through H,-receptors). inhibits gastric acid secretion by virtue of its Hrreceptor Metiamide is also an inhibitor of gastric acid secretion. antagonist activity. Its effectiveness was estimated in two preparations: the Studies are also reported which show that metiamide lumen-perfused stomach of the anaesthetised rat' and given either intravenously or intraduodenally inhibits his­ the conscious Heidenhain pouch dog, prepared 1 - 3 years tamine- or pentagastrin-stimulated acid secretion in human before experimentation. Metiamide was given by rapid subjects. llltravenous injection during a maximal plateau of acid secretion stimulated by either histamine or pentagastrin, and the dose required to reduce this level of secretion by S. Afr. Med. J., 48, 2253 (1974). 50% (ED",) was estimated. The results are shown in Table I and indicate that the ED", values are very similar Conventional antihistaminic drugs, such as mepyramine. even in high concentrations, fail to inhibit histamine­ against those of both histamine and pentagastrin. Doses of stimulated gastric acid secretion.
    [Show full text]
  • United States Patent (19) (11) 4,310,524 Wiech Et Al
    United States Patent (19) (11) 4,310,524 Wiech et al. 45 Jan. 12, 1982 (54) TCA COMPOSITION AND METHOD FOR McMillen et al., Fed. Proc., 38,592 (1979). RAPD ONSET ANTDEPRESSANT Sellinger et al., Fed. Proc., 38,592 (1979). THERAPY Pandey et al., Fed. Proc., 38,592 (1979). 75) Inventors: Norbert L. Wiech; Richard C. Ursillo, Primary Examiner-Stanley J. Friedman both of Cincinnati, Ohio Attorney, Agent, or Firm-Millen & White 73) Assignee: Richardson-Merrell, Inc., Wilton, Conn. (57 ABSTRACT A method is provided for treating depression in a pa (21) Appl. No.: 139,498 tient therefrom and requiring rapid symptomatic relief, (22 Filed: Apr. 11, 1980 which comprises administering to said patient concur 51) Int. Cl. .................... A61K 31/33; A61K 31/135 rently (a) an effective antidepressant amount of a tricy clic antidepressant or a pharmaceutically effective acid (52) ...... 424/244; 424/330 addition salt thereof, and (b) an amount of an a-adrener 58) Field of Search ................................ 424/244, 330 gic receptor blocking agent effective to achieve rapid (56) References Cited onset of the antidepressant action of (a), whereby the PUBLICATIONS onset of said antidepressant action is achieved within Chemical Abst., vol. 66-72828m, (1967), Kellett. from 1 to 7 days. Chemical Abst, vol. 68-94371a, (1968), Martelli et al. A pharmaceutical composition is also provided which is Chemical Abst., vol. 74-86.048j, (1971), Dixit et al. especially adapted for use with the foregoing method. Holmberg et al., Psychopharm., 2,93 (1961). Svensson, Symp. Med. Hoechst., 13, 245 (1978). 17 Claims, No Drawings 4,310,524 1.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Convenient Preparation of Poly(L-Histidine) by the Direct Polymerization of L-Histidine Or Nim Benzyl-L-Histidine with Diphenylphosphoryl Azide
    Polymer Journal, Vol. 13, No. 12, pp 1151-1154 (1981) SHORT COMMUNICATION Convenient Preparation of Poly(L-histidine) by the Direct Polymerization of L-Histidine or Nim_Benzyl-L-histidine with Diphenylphosphoryl Azide Takumi NARUSE, Bun-ichiro NAKAJIMA, Akihiro TSUTSUMI, and Norio NISHI Department of Polymer Science, Faculty of Science, Hokkaido University, Nishi 8-chome, Kita 10-jo, Kita-ku, Sapporo 060, Japan. (Received August 14, 1981) KEY WORDS Polymerization I Diphenylphosphoryl Azide (DPPA) I L- Histidine I N'm-Benzyl-L-histidine I Poly(L-histidine) I Poly(N'm-benzyl-L­ histidine) I IR Spectrum I 13C NMR Spectrum I Intrinsic Viscosity I Poly(L-histidine) is a very interesting poly(a­ histidine) by the polymerization of L-histidine with amino acid) as a synthetic functional polymer or as iodine-phosphonic acid esters was unsuccessful. The a model for the functional biopolymer such as simplification of the synthetic route for poly(L­ enzymes. It is known, however, that poly(L­ histidine) is still necessary. histidine) can not be prepared by the Fuchs­ Diphenylphosphoryl azide (DPPA) has been used Farthing method 1 which is very popular for prepar­ as a convenient reagent for racemization-free pep­ ing poly(a-amino acid)s. A synthetic route with tide synthesis, since it was synthesized by Shioiri et several steps involving the synthesis of NCA (a­ a!. in 1972.6 Recently, we reported that this reagent amino acid N-carboxyanhydride) by the rather can also be used successfully for the polymerization classical Leuchs method/ have been used for the of amino acids or peptides.
    [Show full text]
  • Antagonism of Histamine-Activated Adenylate Cyclase in Brain by D
    Proc. Natl. Acad. Sci. USA Vol.74, No. 12, pp. 5697-5701, December 1977 Medical Sciences Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide (histaminergic antagonists/adenosine 3':5'-cyclic monophosphate/H2-receptors/ergots/D-2-bromolysergic acid diethylamide) JACK PETER GREEN, CARL LYNN JOHNSON, HAREL WEINSTEIN, AND SAUL MAAYANI Department of Pharmacology, Mount Sinai School of Medicine of the City University of New York, 100th Street and Fifth Avenue, New York, New- York 10029 Communicated by Vincent P. Dole, August 19, 1977 ABSTRACT D-Lysergic acid diethylamide and D-2-bro- (ED50; amount necessary to produce half-maximal response) molysergic acid diethylamide are competitive antagonists of and antagonist affinities (pA2) were not altered. the histamine activation of adenylate cyclase [ATP pyrophos- Adenylate Cyclase Assay. The assay system has been de- phate-lyase (cyclizing); E.C. 4.6.1.11 in broken cell preparations in All additions of the hippocampus and cortex of guinea pig brain. The ade- scribed (8). All assays were performed triplicate. nylate cyclase is linked to the histamine H2-receptor. Both D- were made to the assay tubes on ice. They were then transferred lysergic acid diethylamide and D-2-bromolysergic acid dieth- to a 30° shaking incubator and preincubated for 5 min to allow ylamide show topological congruency with potent H2-antago- the enzymatic activity to reach a steady state and to eliminate nists. D-2-Bromolysergic acid diethylamide is 10 times more the influence of any lag periods in hormone activation. After potent as an H2-antagonist than cimetidine, which has been the the preincubation period, 25 of [a-32PJATP (1-2 gCi) were most potent H2-antagonist reported, and D-lysergic acid di- pl ethylamide is about equipotent to cimetidine.
    [Show full text]
  • Title Structure of the Human Histamine H1 Receptor Complex With
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Kyoto University Research Information Repository Structure of the human histamine H1 receptor complex with Title doxepin. Shimamura, Tatsuro; Shiroishi, Mitsunori; Weyand, Simone; Tsujimoto, Hirokazu; Winter, Graeme; Katritch, Vsevolod; Author(s) Abagyan, Ruben; Cherezov, Vadim; Liu, Wei; Han, Gye Won; Kobayashi, Takuya; Stevens, Raymond C; Iwata, So Citation Nature (2011), 475(7354): 65-70 Issue Date 2011-07-07 URL http://hdl.handle.net/2433/156845 © 2011 Nature Publishing Group, a division of Macmillan Right Publishers Limited. Type Journal Article Textversion author Kyoto University Title: Structure of the human histamine H1 receptor in complex with doxepin. Authors Tatsuro Shimamura 1,2,3*, Mitsunori Shiroishi 1,2,4*, Simone Weyand 1,5,6, Hirokazu Tsujimoto 1,2, Graeme Winter 6, Vsevolod Katritch7, Ruben Abagyan7, Vadim Cherezov3, Wei Liu3, Gye Won Han3, Takuya Kobayashi 1,2‡, Raymond C. Stevens3‡and So Iwata1,2,5,6,8‡ 1. Human Receptor Crystallography Project, ERATO, Japan Science and Technology Agency, Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. 2. Department of Cell Biology, Graduate School of Medicine, Kyoto University, Yoshidakonoe-cho, Sakyo-Ku, Kyoto 606-8501, Japan. 3. Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. 4. Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. 5. Division of Molecular Biosciences, Membrane Protein Crystallography Group, Imperial College, London SW7 2AZ, UK. 6. Diamond Light Source, Harwell Science and Innovation Campus, Chilton, Didcot, Oxfordshire OX11 0DE, UK.
    [Show full text]
  • Differential Pulse Polarographic Study of Simple and Mixed Complexes of Copper Ions with the Antidepressant Drug Imipramine and Glutamic Acid Or Histidine
    Differential Pulse Polarographic Study of Simple and Mixed Complexes of Copper Ions with the Antidepressant Drug Imipramine and Glutamic Acid or Histidine M. KHODARI Department of Chemistry, Faculty of Science, South Valley University, Qena, Egypt Received 12 May 1997 The formation of binary and ternary complexes of glutamic acid or histidine and imipramine with Cu(II) has been examined using differential pulse Polarographie technique. The reduction of both simple and mixed systems is reversible and controlled by diffusion. The obtained results reveal the formation of mixed complexes. For the system Cu—Glu—Imip, one mixed complex was formed: Cu(Glu)(Imip)2 with stability constant log{/3i2} = 10.51, while the system Cu—His— Imip forms two complexes Cu(His)(Imip) and Cu(His)(Imip)2 with stabilities log{/?n} = 6.25 and log{/?i2} = 8.77, respectively. These experimental values were compared with the statistical ones. Mixed complexes are usually formed when the Histidine and other amino acids are involved in metal ion is present in a mixture of two or more com- copper(II) transport in blood and exchange interac­ plexing species in solution [1—3]. Different electro­ tions with serum albumin [13]. Imipramine is one of chemical techniques were applied to study such sys­ the most widely used drugs for the treatment of de­ tems [4—6]. The method of DeFord and Hume [7] as pression [14]. Hence their binary and ternary com­ extended by Schaap and McMasters [1] was used to plexes are of great interest. So the present work is calculate the formation constants of the mixed system aimed to study the expected formed complexes be­ using direct current Polarographie technique.
    [Show full text]
  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
    1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure
    [Show full text]